"Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor" in Patent Application Approval Process (USPTO 20240197742).

A patent application has been filed for a therapeutic combination of a CD19 inhibitor and a BTK inhibitor for the treatment of various types of cancers, as well as inflammatory, immune, and autoimmune disorders. The combination of these inhibitors has shown effectiveness in treating hyperproliferative diseases. The patent application also suggests that the combination of an anti-CD20 antibody with the CD19 and BTK inhibitors may be effective in treating these diseases. The patent application describes a method of treating hyperproliferative diseases, particularly cancer, by co-administering a CD19 inhibitor and a BTK inhibitor, and also includes the use of gemcitabine or albumin-bound paclitaxel in combination with the inhibitors. The invention encompasses the use of specific cancers, inhibitors, and additional therapies in combination with the CD19 and BTK inhibitors. [Extracted from the article]